Universal LCAR-BCX cell therapy - Nanjing Legend Biotech
Alternative Names: LCAR-BCX CAR cell therapy - Nanjing Legend Biotech; LCAR-BCX cells product - Nanjing Legend BiotechLatest Information Update: 28 Nov 2023
At a glance
- Originator Nanjing Legend Biotech
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- No development reported Multiple myeloma
Most Recent Events
- 28 Nov 2023 No recent reports of development identified for phase-I development in Multiple-myeloma(Second-line therapy or greater) in China (IV, Infusion)
- 26 Oct 2020 Universal LCAR-BCX cell therapy - Nanjing Legend Biotech is available for licensing as of 02 Nov 2020. https://www.legendbiotech.com/about.php#partnerships (Nanjing Legend Biotech Website, November 2020)
- 09 Oct 2020 Phase-I clinical trials in Multiple myeloma (Second-line therapy or greater) in China (IV) (NCT04601935)